Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.

NDLS gastric adenocarcinoma gastroesophageal junction adenocarcinoma nanosomal docetaxel lipid suspension

Journal

Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 25 02 2020
accepted: 15 05 2020
entrez: 6 8 2020
pubmed: 6 8 2020
medline: 6 8 2020
Statut: ppublish

Résumé

The current retrospective multicenter study evaluated the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS; DoceAqualip) based chemotherapy in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The medical charts of patients with gastric and GEJ adenocarcinoma, who were treated with NDLS (50-75 mg/m

Identifiants

pubmed: 32754328
doi: 10.3892/mco.2020.2084
pii: MCO-0-0-02084
pmc: PMC7391841
doi:

Types de publication

Journal Article

Langues

eng

Pagination

14

Informations de copyright

Copyright © 2020, Spandidos Publications.

Références

J Clin Oncol. 2010 May 1;28(13):2213-9
pubmed: 20351330
J Clin Oncol. 2007 Aug 1;25(22):3217-23
pubmed: 17664469
Iran J Cancer Prev. 2013 Summer;6(3):133-40
pubmed: 25250123
Ann Oncol. 2001 Jan;12(1):47-51
pubmed: 11249048
Clin Oncol (R Coll Radiol). 2011 Oct;23(8):560-1
pubmed: 21571513
Med Oncol. 1996 Jun;13(2):87-93
pubmed: 9013471
World J Surg Oncol. 2019 Jan 3;17(1):3
pubmed: 30606195
BMJ. 2005 Oct 22;331(7522):951-3
pubmed: 16239692
Gastric Cancer. 2009;12(3):132-41
pubmed: 19890692
J BUON. 2013 Jan-Mar;18(1):147-53
pubmed: 23613400
Gastric Cancer. 2002;5(3):142-7
pubmed: 12378340
Clin Breast Cancer. 2014 Jun;14(3):177-81
pubmed: 24287370
Acta Oncol. 2003;42(7):693-700
pubmed: 14690154
Clin Pharmacokinet. 2003;42(7):665-85
pubmed: 12844327
Nature. 2019 Mar;567(7749):540-544
pubmed: 30867597
Nat Rev Dis Primers. 2017 Jun 01;3:17036
pubmed: 28569272
Ther Clin Risk Manag. 2008 Oct;4(5):999-1007
pubmed: 19209281
Ann Allergy Asthma Immunol. 2005 Dec;95(6):593-9
pubmed: 16400901
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 2012 Jul 24;107(3):435-41
pubmed: 22767144
Gastric Cancer. 2009;12(2):69-78
pubmed: 19562460
Oncologist. 2007 Feb;12(2):175-85
pubmed: 17296813
Oncologist. 2019 Aug;24(8):1039-e642
pubmed: 31138725
Gastrointest Tumors. 2014 Jun;1(2):99-104
pubmed: 26675677
Mol Clin Oncol. 2017 Mar;6(3):341-343
pubmed: 28451410
Adv Ther. 2018 Jun;35(6):754-767
pubmed: 29796927
Jpn J Clin Oncol. 2002 Jul;32(7):248-54
pubmed: 12324575
Clin Cancer Res. 2007 Jun 1;13(11):3302-11
pubmed: 17545536
Cancer Manag Res. 2014 May 27;6:253-9
pubmed: 24904223
BMJ Case Rep. 2017 Nov 12;2017:
pubmed: 29133580
Mol Clin Oncol. 2018 Feb;8(2):296-299
pubmed: 29435291
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 2011 Aug 9;105(4):505-12
pubmed: 21792201
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
J Clin Oncol. 1990 Jul;8(7):1263-8
pubmed: 1972736

Auteurs

Sundaram Subramanian (S)

Department of Medical Oncology, VS Hospital, Madras Cancer Institute, Advanced Cancer Care, Chennai, Tamil Nadu 600031, India.

Saroj Kumar Das Majumdar (SKD)

Department of Radiotherapy, All India Institute of Medical Sciences, Bhubaneswar, Odisha 751019, India.

Ghanashyam Biswas (G)

Department of Medical Oncology, Sparsh Hospital, Bhubaneswar, Odisha 751007, India.

Nisarg Joshi (N)

Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Sola, Ahmedabad, Gujarat 380054, India.

Deepak Bunger (D)

Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Sola, Ahmedabad, Gujarat 380054, India.

Mujtaba Ali Khan (MA)

Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Sola, Ahmedabad, Gujarat 380054, India.

Imran Ahmad (I)

Jina Pharmaceuticals Inc., Libertyville, IL 60048, USA.

Classifications MeSH